Please login to the form below

Not currently logged in

Covance expands its clinical trials capabilities across Asia Pacific

New laboratory doubles CRO’s genomics footprint in Singapore

Clinical research organisation (CRO) Covance has announced the completion of its Singapore laboratory facility expansion.

The New Jersey, US-headquartered CRO says the development will enhance the company's service offerings in the Asia Pacific region.

The Singapore development marks the latest in a number of recent investments the company has made in the region, which includes growth of its operations in China and Japan.

“For the last 13 years Covance has provided central laboratory testing services in Singapore, where we have seen increasing demand for efficient, high-quality clinical trial data and support,” said Jon Koch, corporate VP and global general manager, Central Laboratory Services, Covance.

“This expansion will help us better serve both our local and multinational customers' R&D needs in key therapeutic areas like oncology and metabolic diseases, while reflecting Covance's continued commitment to the Asia Pacific region.”

At approximately 2,700 square metres, the new laboratory is the largest of its kind in Singapore and will provide clinical testing services for clients from South Korea, Taiwan, Hong Kong, the Philippines, Australia and India.

The facility will provide a full-service offering, covering chemistry, immunology, haematology, flow cytometry, genomics, anatomic pathology and microbiology.

Commenting on the investment in Singapore, Kevin Lai, director, Biomedical Sciences Group, from the Economic Development Board of Singapore, said: “Covance's expansion reaffirms Singapore's proposition as a strategic location for CROs to base their regional operations as they expand to tap on the fast growing opportunities in Asia.

“Its investment is a strong vote of confidence in our efforts in developing Singapore as a leading biomedical sciences hub with strong capabilities to support translational and clinical research.”

19th April 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...